Vernalis PLC Block listing Interim Review (5737C)
01 Ottobre 2018 - 3:57PM
UK Regulatory
TIDMVER
RNS Number : 5737C
Vernalis PLC
01 October 2018
BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING
APPLICATION
VERNALIS PLC (the "Company")
1 October 2018
Vernalis plc (LSE: VER) provides the following update in
accordance with Schedule Six of the AIM Rules for Companies
regarding its existing block listing arrangements:
Name of applicant: Vernalis plc
Name of scheme(s): 2007 Long Term Incentive Scheme
("LTIP"); 2012 Value Builder Plan
("VBP"); and
2016 Executive Incentive Plan
("EIP")
--------------------------------------------------
Period of return (from From: 29/Mar/2018 To: 01/Oct/2018
/ to):
-------------------------- ----------------------
Balance of unallotted securities Total of 2,149,159 Ordinary 1p
under scheme(s) from previous Shares, split:
return: * Under LTIP = 360,485 Ordinary 1p Shares
* Under VBP = 1,788,674 Ordinary 1p Shares
* Under EIP = nil Ordinary 1p Shares
--------------------------------------------------
Plus: The amount by which NIL
the block scheme(s) has
been increased or application
has been made to increase
since the date of the last
return (if any increase
has been applied for):
--------------------------------------------------
Less: Number of securities Total of 166,376 Ordinary 1p Shares,
issued/allotted under scheme(s) split:
during period: * Under LTIP = 39,405 Ordinary 1p Shares
* Under VBP = 126,971 Ordinary 1p Shares
--------------------------------------------------
Less: Number of securities Total of 30,526 Ordinary 1p Shares:
forfeited under scheme(s) * Under LTIP = 30,526 Ordinary 1p Shares
during period:
* Under VBP = nil Ordinary 1p Shares
* Under EIP = nil Ordinary 1p Shares
--------------------------------------------------
Equals: Balance under scheme(s) Total of 1,952,257 Ordinary 1p
not yet issued/allotted Shares, split:
at end of period: * Under LTIP = 290,554 Ordinary 1p Shares
* Under VBP = 1,661,703 Ordinary 1p Shares
* Under EIP = nil Ordinary 1p Shares
--------------------------------------------------
Number and class of securities No. of Ordinary Date on which Shares
originally admitted and 1p Shares were Admitted to
the date of admission (including Trading
any additions): 350,000 6 November 2013,
plus
---------------------
1,049,317 12 May 2014, plus
---------------------
1,058,184 12 May 2015, plus
---------------------
1,638,364 30 September 2015,
plus
---------------------
1,189,296 1 April 2016, plus
---------------------
499,612 31 March 2017, plus
---------------------
1,788,674 2 October 2017, plus
---------------------
95,654 5 April 2018
---------------------
--------------------------------------------------
-- ends --
Enquiries:
Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
Canaccord plc (Nominated Adviser and
Broker): +44 (0) 20 7523 8000
Henry Fitzgerald-O'Connor
Emma Gabriel
Evercore (Financial Adviser): +44 (0) 20 7653 6000
Julian Oakley
Alan Beirne
Notes to Editors
About Vernalis
Vernalis is a revenue generating, pharmaceutical company with
significant expertise in drug development. The Group has two
approved products: Moxatag(R) , a once-daily formulation of the
antibiotic, amoxicillin, indicated for the treatment of tonsillitis
and/or pharyngitis secondary to Streptococcus pyogenes in adults
and pediatric patients 12 years and older; and frovatriptan for the
acute treatment of migraine. Vernalis has also nine programmes in
its NCE development pipeline in addition to significant expertise
in fragment and structure based drug discovery which it leverages
to enter into collaborations with larger pharmaceutical companies.
The Company's technologies, capabilities and products have been
endorsed over the last five years by collaborations with leading
pharmaceutical companies, including Asahi Kasei Pharma, Biogen
Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini,
Novartis and Servier.
For further information about Vernalis, please visit
www.vernalis.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BLRMBBJTMBAMBJP
(END) Dow Jones Newswires
October 01, 2018 09:57 ET (13:57 GMT)
Grafico Azioni Vernalis (LSE:VER)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Vernalis (LSE:VER)
Storico
Da Mag 2023 a Mag 2024